Jyong Biotech Ltd.

Taiwan botanical-drug developer whose lead candidate Botreso failed its U.S. Phase III primary endpoint.

Strengths

• Recently completed IPO raising ~$17.8M net; positive accounting ROE (81st pct)
• Integrated drug-development capabilities and multiple urology indications

Risks

• Pivotal Phase III for Botreso failed to show statistically significant efficacy vs placebo; NDA withdrawn and program must restart with new API-2
• Weak liquidity (current ratio 0.45, 9.6th pct); active Taizhou land litigation with adverse judgment; positive ROE is a negative-equity artifact

Notable findings

• Negative equityNegative book equity (debt/equity -0.09)
• Weak liquidityCurrent ratio 0.45 (<1)